

New Treatment Option for Dogs and Cats with Incompletely Resected Tumors

Clinical Trial Opportunities Available

Historically, stereotactic radiation (SRS/SRT) has not been recommended for pets that have microscopic residual disease after surgical tumor resection, primarily because there is no clearly definable treatment target.

PetCure Oncology recently completed a pilot study evaluating the utility of a liquid fiducial, PetXMark™, to establish a SRS/SRT planning target volume in dogs. This study showed that PetXMark™ was well tolerated and had no acute side effects.

Clinical Trial Enrollment

If you have questions about enrollment criteria or would like to refer an animal for evaluation/inclusion in the study, contact:

*Brandy Banks, RT(R)(T)
Clinical Trials Coordinator
PetCure Oncology
ClinicalTrials@PetCureOncology.com
844.308.2578*

*or visit our website at
PetCureOncology.com/ClinicalTrials/*

Main Trial

PetCure Oncology is currently recruiting 50-60 participants for a clinical trial evaluating the effectiveness of SRS/SRT combined with PetXMark™ for the treatment of incompletely resected, grade 2 soft tissue sarcoma in dogs.

This will be the first controlled, prospective clinical study in veterinary oncology designed to define the risks and benefits of this kind of radiation therapy for microscopically incompletely resected tumors.

Supplementary Trial

PetCure Oncology is also offering PetXMark™ to enable the delivery of SRS/SRT to dogs and cats with incompletely resected cancers that are not candidates for the Main Trial, and may not otherwise be candidates for SRS/SRT.

Preliminary data indicate this liquid fiducial is safe and effective. Our goal in offering this ancillary option is to provide pets and their families with broader access to advanced and revolutionary cancer treatment.

What is PetXMark™?

PetXMark™, a liquid fiducial marker, can be injected along a surgical incision or painted into a resection cavity and will be visible on subsequent imaging.¹ This allows an artificial target to be created that can then be treated with SRS/SRT in a single fraction, rather than the 15-20 fractions typically recommended for the treatment of an incompletely resected tumors with conventionally fractionated radiation therapy (CFRT).

1. Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølcck RI, Josipovic M, Aznar M, Specht L, Andresen TL, Rosenschöld PM, Persson GF: Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer, *Radiotherapy and Oncology* (2016); Volume 121, Issue 1, Pages 64–69.